# The Relationship between Extensively Drug-Resistant Tuberculosis and Multidrug-Resistant Gram-Negative Bacilli

**Authors:** Jiang-nan Zhao, Xian-xin Zhang, Xiao-chun He, Guo-ru Yang, Xiao-qi Zhang, Huai-chen Li

PMC · DOI: 10.1371/journal.pone.0134998 · 2015-07-31

## TL;DR

This study found that patients with extensively drug-resistant tuberculosis are more likely to also have multidrug-resistant Gram-negative bacteria infections.

## Contribution

The study identifies a significant association between XDR-TB and MDR-GNB infections in pulmonary TB patients.

## Key findings

- XDR-TB patients had a 24.4% occurrence of MDR-GNB compared to 4.5% in non-XDR-TB patients.
- XDR-TB was an independent risk factor for MDR-GNB infection (OR 6.56).

## Abstract

The relationship between extensively drug-resistant tuberculosis (XDR-TB) and multidrug-resistant Gram-negative bacilli (MDR-GNB) is unclear. Identification of the relationship between XDR-TB and MDR-GNB would have important implications for patient care.

We conducted a retrospective study reviewing the records of patients admitted with a confirmed pulmonary TB from 2011 to 2014. To identify the relationship between XDR-TB and MDR-GNB, univariable comparison and multivariable logistic regression were performed.

Among 2962 pulmonary TB patients, 45(1.5%) patients had a diagnosis of XDR-TB. A total of 165 MDR-GNB strains were detected in 143 (4.8%) pulmonary TB patients. XDR-TB patients had a significantly higher occurrence of MDR-GNB than non-XDR-TB patients (24.4% vs. 4.5%; P<0.001). Age (OR 1.02, 95% CI 1.01–1.03), hypoalbuminemia (OR 1.48, 95% CI 1.18–1.85), chronic renal failure (OR 6.67, 95% CI 1.42–31.47), chronic hepatic insufficiency (OR 1.99, 95% CI 1.15–3.43), presence of XDR-TB (OR 6.56, 95% CI 1.61–26.69), and duration of TB diagnostic delay (OR 1.01, 95% CI 1.00–1.02) were the independent risk factors for MDR-GNB infection.

Patients with XDR-TB have a significantly higher risk of being affected by MDR-GNB pathogen. The underlying mechanism association warrant further studies.

## Linked entities

- **Diseases:** tuberculosis (MONDO:0018076), XDR-TB (MONDO:0100482), pulmonary TB (MONDO:0006052), chronic renal failure (MONDO:0024327)

## Full-text entities

- **Diseases:** gastrointestinal infection (MESH:D005767), Infection (MESH:D007239), -GNB (MESH:D016905), Tuberculosis (MESH:D014376), Chronic pulmonary disease (MESH:D002908), Extra-pulmonary TB (MESH:D000092225), Extensively Drug-Resistant Tuberculosis (MESH:D054908), skin and soft tissue infection (MESH:D018461), pulmonary infection (MESH:D012141), impaired (MESH:D060825), Chronic hepatic insufficiency (MESH:D048550), Gastric ulcer (MESH:D013276), Hospital mortality (MESH:D003643), bone and joint infection (MESH:D001847), Anemia (MESH:D000740), urinary tract infection (MESH:D014552), pleural effusion (MESH:D010996), central nervous system infection (MESH:D002494), connective tissue disease (MESH:D003240), wound infection (MESH:D014946), MDR (MESH:D018088), Cavity lesion (MESH:D003731), reproductive tract infection (MESH:D060737), Hospital (MESH:D003428), chronic obstructive pulmonary disease (MESH:D029424), Chronic renal failure (MESH:D007676), bacterial infection (MESH:D001424), -TB (MESH:D014390), cardiovascular system infection (MESH:D053821), Chronic pulmonary diseasea (MESH:D055370), asthma (MESH:D001249), pulmonary symptoms (MESH:D012818), bacteremia (MESH:D016470), cerebrovascular disease (MESH:D002561), Hypoalbuminemia (MESH:D034141), bronchiectasis (MESH:D001987), bacterial pneumonia (MESH:D018410), eye, ear, nose, throat, and mouth infection (MESH:D010031),  (MESH:D014397)
- **Chemicals:** cephalosporins (MESH:D002511), penicillins (MESH:D010406), ceftriaxone (MESH:D002443), amikacin (MESH:D000583), capreomycin (MESH:D002207), streptomycin (MESH:D013307), imipenem (MESH:D015378), aminoglycosides (MESH:D000617), carbapenems (MESH:D015780), monobactams (MESH:D008997), fluoroquinolone (MESH:D024841), piperacillin (MESH:D010878), alcohol (MESH:D000438), penicillin G (MESH:D010400), pyrazinamide (MESH:D011718), gentamicin (MESH:D005839), aztreonam (MESH:D001398), ofloxacin (MESH:D015242), Hinton (-), moxifloxacin (MESH:D000077266), ampicillin/sulbactam (MESH:C035444), ticarcillin (MESH:D013982), ethambutol (MESH:D004977), ciprofloxacin (MESH:D002939), kanamycin (MESH:D007612), ceftazidime (MESH:D002442), isoniazid (MESH:D007538), rifampicin (MESH:D012293), cefepime (MESH:D000077723), levofloxacin (MESH:D064704), meropenem (MESH:D000077731), para-aminosalicylic acid (MESH:D010131)
- **Species:** Acinetobacter baumannii (species) [taxon 470], Enterobacter cloacae (species) [taxon 550], Haemophilus influenzae (species) [taxon 727], Centipeda dianae (species) [taxon 135079], Morganella morganii (species) [taxon 582], Serratia marcescens (species) [taxon 615], Pseudomonas aeruginosa (species) [taxon 287], Achromobacter xylosoxidans (species) [taxon 85698], Stenotrophomonas maltophilia (species) [taxon 40324], Pseudomonas luteola (species) [taxon 47886], Serratia liquefaciens (species) [taxon 614], Acinetobacter lwoffii (species) [taxon 28090], Chryseobacterium indologenes (species) [taxon 253], Citrobacter freundii (species) [taxon 546], Mycobacterium tuberculosis (species) [taxon 1773], Aeromonas hydrophila (species) [taxon 644], Klebsiella aerogenes (species) [taxon 548], Escherichia coli (E. coli, species) [taxon 562], Moraxella catarrhalis (species) [taxon 480], Human immunodeficiency virus (species) [taxon 12721], Burkholderia cepacia (species) [taxon 292], Klebsiella pneumoniae (species) [taxon 573], Shewanella putrefaciens (species) [taxon 24], Klebsiella oxytoca (species) [taxon 571], Enterobacter asburiae (species) [taxon 61645], Homo sapiens (human, species) [taxon 9606], Proteus mirabilis (species) [taxon 584]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC4521689/full.md

---
Source: https://tomesphere.com/paper/PMC4521689